Thousands of doses of smallpox vaccine being prepared

Thousands of doses of smallpox vaccine being prepared

As of Monday, May 5, 2025, a supplier for a large batch of the so-called "windpox" (colloquially known as "vetraianka") vaccines is being sought through the government procurement portal. According to the documentation, the procurement involves approximately 3,000 doses to be delivered before December 15, 2025.

It's important to note that these quantities do not represent the largest recorded in recent years. For instance, in 2022, roughly 8,000 doses were procured. This followed a significant spike in windpox cases in the region. Between January and July, there were 8,791 reported cases (+92% compared to the previous year), according to official statistics. In 2023, the number of detected cases continued to rise, totaling more than 10,000 occurrences.

Remember, the Russian Rospotrebnadzor defines windpox as "a severe viral infectious disease characterized by skin and mucous membrane rashes in various forms, a moderately severe fever, and symptoms of general intoxication."

Evgeny Kuplienko

• Topics: Society, Healthcare, Procurement

Join our channel on Yandex Zen.

Health News (Latest Omsk News)* VKontakte* Ok, My World**

Print Version

Epidemiological Background

Given the lack of specific information about windpox vaccine procurement, case numbers, or acquisition details in Russia as of May 5, 2025, the following is a general analysis of relevant vaccine trends and procurement mechanisms that could apply to similar scenarios:

Key Insights on Vaccine Procurement (General assumptions)

1. WHO Standards: The WHO recommends vaccines with a minimum of 50% efficacy for global use and aims to achieve 90% coverage of essential vaccines by 2030[1]. Normally, vaccine development takes over a decade (pre-COVID averages: 10+ years), but emergency situations can expedite the process (e.g., Operation Warp Speed managed to develop COVID-19 vaccines in months)[1].
2. Shift in Regulatory Approaches: The U.S. HHS announced stricter placebo trial requirements in May 2025, which may complicate approvals for improved vaccines (such as for whooping cough and potential COVID-19 boosters)[2]. Whilst these changes might indirectly impact global regulations, there's no direct link to Russia in the available data.
3. Global Procurement Models:
4. China's Role: China supplied around 50% of the global COVID-19 vaccines (over 2.3 billion doses to 120+ countries)[4], demonstrating its potential as a major supplier.
5. Pandemic Agreements: Proposals have emphasized equitable distribution, though specifics for non-COVID vaccines remain unclear[3].

Hypothetical Application to Russia

• Procurement Sources: Historically, Russia depends on domestic production (like the Sputnik V COVID-19 vaccine) and partnerships with countries such as China for raw materials[^general_knowledge]. There's no specific information regarding the "windpox" vaccine in the available data.
• Case Reporting: Without disclosed data, trends are speculative. Platforms like the WHO's Global Health Observatory or Russia's federal health agency would usually provide updates.

Research Suggestions

1. Terminology Clarification: Determine whether "windpox" refers to a known illness (for example, chickenpox or monkeypox) or a localized term.
2. Regional Resources: Investigate Russian-language health bulletins or agencies like Rospotrebnadzor for case counts.
3. Global Databases: Consult WHO's Vaccine-Preventable Diseases Monitoring System or Gavi's procurement reports for indirect insights.

If additional context or corrected terminology is provided, a more targeted analysis can be performed.

1. The vendor for a bulk quantity of the windpox vaccines is being searched through the government procurement portal as of May 5, 2025.
2. The procurement entails approximately 3,000 doses to be delivered before December 15, 2025.
3. These amounts do not represent the highest recorded in recent years, with 8,000 doses procured in 2022 following a spike in windpox cases.
4. In 2023, the number of detected cases continued to increase, totaling over 10,000 occurrences.
5. Windpox, as defined by the Russian Rospotrebnadzor, is a severe viral infectious disease with skin and mucous membrane rashes, a moderately severe fever, and symptoms of general intoxication.
6. Evgeny Kuplienko discusses the current windpox vaccine procurement, along with related societal, healthcare, and procurement issues, in a deeper context.
7. Subscribers can find updates on these topics through Yandex Zen, VKontakte, Ok, My World, and the print version.
8. The WHO recommends vaccines with at least 50% efficacy for global use, aiming for 90% coverage of essential vaccines by 2030.
9. Vaccine development usually takes over a decade, but emergency situations can expedite the process, as demonstrated during the COVID-19 pandemic.
10. The U.S. HHS announced stricter placebo trial requirements in May 2025, which might affect approvals for improved vaccines.
11. China supplied over 50% of the global COVID-19 vaccines, demonstrating its potential as a significant supplier.
12. Proposals have emphasized equitable distribution for non-COVID vaccines, but specifics remain unclear.
13. Historically, Russia depends on domestic production and partnerships with countries such as China for raw materials.
14. Without disclosed data, trends related to windpox are speculative, with platforms like the WHO's Global Health Observatory or Russia's federal health agency typically providing updates.
15. Determining whether "windpox" refers to a known illness, like chickenpox or monkeypox, or a localized term could provide further insight.
16. Investigating Russian-language health bulletins or agencies like Rospotrebnadzor for case counts is also crucial.
17. Consulting WHO's Vaccine-Preventable Diseases Monitoring System or Gavi's procurement reports could offer indirect insights into the windpox situation.
18. A more targeted analysis can be performed with additional context or corrected terminology.
19. Equitable vaccine distribution, regardless of the disease, should be a priority for combatting global health threats.
20. Regional differences in vaccine accessibility and affordability must also be considered.
21. Collaborative efforts among countries and international organizations are essential to ensure a rapid response during emergency situations.
22. Therapies and treatments for windpox should be a focus of research, as they could help reduce the severity and impact of the disease.
23. Improving our understanding of the underlying causes of windpox is crucial for developing effective preventative measures and treatments.
24. Public awareness about the disease, its preventative measures, and the importance of vaccination is vital for its control.
25. Industry collaboration with scientists, healthcare providers, and government agencies could facilitate the development of more effective strategies for managing windpox.
26. Continued investment in research, development, and manufacturing of antiviral therapies and vaccines is essential to combat windpox and other emerging infectious diseases.
27. Proper allocation of resources, both financial and human, is crucial to ensure the successful development and implementation of new vaccines.
28. Ongoing effort to improve testing and diagnostic capabilities is needed to accurately identify, track, and control the spread of windpox.
29. Community engagement and education in health and wellness practices can help minimize the spread of infectious diseases like windpox.
30. Addressing underlying medical conditions, such as chronic diseases, can bolster individuals' immune systems and make them less susceptible to windpox and other infections.

Read also: